Nsp3 Mac1 - C2 (UCSF)
(Plasmid
#169209)
-
PurposeExpression of 6xHis tagged protein for crystallization, includes TEV protease site for tag removal
-
Depositing Lab
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 169209 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 * | |
* Login to view industry pricing.
Backbone
-
Vector backbonepET22b(+)
- Backbone size w/o insert (bp) 5358
- Total vector size (bp) 5928
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSARS-CoV-2 Nsp3 Mac1
-
Alt nameNsp3 ADRP
-
SpeciesSARS-CoV-2
-
Insert Size (bp)561
-
GenBank IDNC_045512.2
- Promoter T7
-
Tag
/ Fusion Protein
- 6xHis (N terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NdeI (not destroyed)
- 3′ cloning site XhoI (not destroyed)
- 5′ sequencing primer T7 Fwd (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byGenscript
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Trademarks:
- Zeocin® is an InvivoGen trademark.
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Nsp3 Mac1 - C2 (UCSF) was a gift from James S Fraser (Addgene plasmid # 169209 ; http://n2t.net/addgene:169209 ; RRID:Addgene_169209) -
For your References section:
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking. Schuller M, Correy GJ, Gahbauer S, Fearon D, Wu T, Diaz RE, Young ID, Carvalho Martins L, Smith DH, Schulze-Gahmen U, Owens TW, Deshpande I, Merz GE, Thwin AC, Biel JT, Peters JK, Moritz M, Herrera N, Kratochvil HT, Aimon A, Bennett JM, Brandao Neto J, Cohen AE, Dias A, Douangamath A, Dunnett L, Fedorov O, Ferla MP, Fuchs MR, Gorrie-Stone TJ, Holton JM, Johnson MG, Krojer T, Meigs G, Powell AJ, Rack JGM, Rangel VL, Russi S, Skyner RE, Smith CA, Soares AS, Wierman JL, Zhu K, O'Brien P, Jura N, Ashworth A, Irwin JJ, Thompson MC, Gestwicki JE, von Delft F, Shoichet BK, Fraser JS, Ahel I. Sci Adv. 2021 Apr 14;7(16). pii: 7/16/eabf8711. doi: 10.1126/sciadv.abf8711. Print 2021 Apr. 10.1126/sciadv.abf8711 PubMed 33853786
